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Introduction
An initiative to improve the safety of infusion pumps was announced by the Food and Drug Administration (FDA) in April 2010 following 56,000 adverse event (AE) reports and 87 infusion pump recalls over the previous 4 years, mainly involving in-hospital intravenous infusion pumps. Alarmingly, 14 of the recalls were class I, defined as a reasonable probability that the use of the device will cause serious adverse health consequences or death. These issues were observed across different manufacturers, types of pumps, and use environments. The most common types of reported problems have been associated with software defects, user interface issues, and mechanical or electrical failures. Increasing concerns by the FDA resulted in new requirements being established for the pump manufacturers. 1 Insulin pumps make up a small portion of all medical infusion pumps, although their number is increasing by approximately 10% per year, 2 following the increase in diabetes worldwide. In May 2008, the FDA published the results of a retrospective 10-year study (1996) (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) of AE reports of insulin and analgesia pumps by adolescents (12 to 21 years old). 3 There was a total of 1594 AE reports regarding insulin pump use. Reported events included injuries (65.1%), malfunctions (33.1%), "other events" (0.9%), and death in 13 patients (0.8%). Reported deaths were related to either hyperglycemic or hypoglycemic complications (n = 5), diabetic ketoacidosis (DKA; n = 3), seizure (n = 1), coma (n = 1), or nonindicated cause (n = 3). Hyperglycemia was reported in 987 (61.9%) events, of which 46.6% involved DKA. Overdelivery of insulin and/or hypoglycemia events were reported in 167 (10.5%) reports. Primary issues causing the events were reported as educational faults, noncompliance, and issues during activities such as sports. Further perfection of technology and design of insulin pumps is required in order to assure ease of use, safety, and compliance. Of note is the fact that there is no good comparison group for AEs related to the use of insulin vials/syringes/ pens. A majority of the "pump" events may not have anything to do with the pump but may be related to patient behaviors and insulin dosing decisions. Before reaching the market, insulin pumps must obtain FDA approval and undergo rigorous testing by manufacturers to meet required standards such as the International Electrotechnical Commission 60601-2-24.
The OmniPod Insulin Management System (Insulet, Bedford, MA) is currently an integral part of the Artificial Pancreas Project sponsored by the Juvenile Diabetes Research Foundation. The artificial pancreas system (APS) is a system for automating closed-loop glucose control, comprising a glucose sensor, a controller/algorithm, human user interface, and an insulin pump. 4 During discussions for an investigational device exemption and master file (FDA MAF #1625) submission of the APS, we received a request from the FDA to reconfirm the dose accuracy of the FDA-approved OmniPod as an integral part of the APS. They wanted our group to demonstrate that the pump was accurate at its lowest dosing increment. The control algorithm of the APS calculates the amount of insulin to be delivered based on frequent glucose input data from a continuous glucose sensor. Assuring the accuracy of the pump is an integral step in the validation process. The FDA believed there was a need for additional bench test data to support the accuracy of the OmniPod at the smallest delivery volume.
To address this concern, we implemented method 1 (discussed later), to measure the accuracy of the OmniPod using a standard graduated pipette. After submitting the results, the FDA requested additional bench testing. We were also asked to provide justification of the fact that the measuring error is independent of the insulin amount to be measured. To answer these concerns, we implemented method 2 and provided theoretical statistical explanations (discussed later).
Interestingly, in silico research by Chan and colleagues 5 has shown that random pump errors with standard deviations (SDs) up to 10% of the expected pump output do not cause significant plasma insulin variability with pulsatile injections. This finding requires additional in vivo verification for clinical and further research significance.
Methods
We implemented two new approaches for assessing pump accuracy. A total of seven OmniPod insulin pumps were tested at bolus doses of 0.05, 0.1, 0.2, 1, and 6 U. Additional materials included a digital microscope (DinoLight, running software DinoXcope v1.1) and a standard 100 µl pipette (equivalent to a 10 U volume of insulin). Using these simple tools, we were able to calculate the delivered volumes and its variability. Each method had its own strengths and weaknesses. Method 1, for example, was better suited for measuring insulin doses above 0.2 U because of the size of the pipette. Although, using standard statistical techniques, 6 method 1 could be used to look at the accuracy and precision of smaller boluses. Method 2, as described later, will only work for the smallest bolus delivery volume but would be the best way to measure accuracy of these small volumes.
Method 1
Pipette A standard pipette was used as a linear measure tool to assess the amount of insulin delivered by the pump. Insulin (Humalog, Lilly, Indianapolis, IN) was tinted red with a drop of food coloring (McCormick, Sparks, MD) to aid in visualization. Five OmniPods were used for this experiment. Pumps were filled with insulin according to the manufacturer's instructions. Once activated and ready to be used, the distal tip of the OmniPod's cannula was fitted into the end of the pipette (see Figures 1-3 ). We performed multiple runs of each OmniPod at each of the following doses: 0.05, 0.1, 0.2, 1.0, and 6 U. For the 0.05, 0.1, and 0.2 doses, we estimated accuracy over a series of delivered doses. The reasoning for this is that it is very difficult to precisely measure individual dose of 0.05 U using a pipette of this size. Attempts were made to use smaller pipettes, but we were unsuccessful because of the mismatch of the inner diameter of the pipette and the outer diameter of the cannula (see which demonstrates air bubbles interfering with the accurate measurement when we attempted to use 0.5 and 1.0 µl pipettes). We estimated accuracy over 20 doses (0.05 × 20 = 1 U) and 10 doses for 0.1 and 0.2 U. Measuring 1 or 2 U provides less measuring error and thus is more accurate for estimation of the pump performance. The level of fluid in the pipette was measured to and from the meniscus level.
The cannula's graduations are too large to measure the volumes < 1 µl (0.1 U) accurately. Images from the microscope were additionally magnified to fit a 13" computer screen (MacBook, Apple, Cupertino, CA) using Adobe Reader software (v7.07). The volume level in the pipette was measured with a pixel precision using a standard metric ruler. Using a proportion with a known volume of 0.1 U (one small graduation), the given volume can be measured (see Figures 1-5) .
Statistics
The challenge of measuring the accuracy of such small single insulin doses stems from the fact that the error of direct measurement is comparable to the measured quantities. The basic premise of the test methodology proposed here is that better estimates of single-dose properties can be obtained by considering the sum of multiple doses. The proposed solution is outlined as follows:
• When assessing pump accuracy, errors in insulin delivery (e.g., pump errors) must be distinguished from errors in the measurement of the delivered insulin (measurement errors).
• Assessment of errors in insulin delivery is of primary interest. Therefore, measurement methodology should be designed in a way that reduces the influence of measurement errors.
• In order to do so, we rely on classic techniques designed to use repeated measurements to reduce the uncertainty of measurement.
Thus we claim that repeated measurements of the sum of several single doses would yield a more precise estimate of the distribution of any single dose than the measurement of individual doses. Mathematical justification of this assertion is straightforward and is described in the Appendix. Intuitively, if we measure every single dose n times, we have n chances to make a measurement error. If we measure only the sum of several single doses, we have only one chance to make a measurement error of the same magnitude. Thus, when measuring every single pump pulse, we amplify the error in insulin delivery by the error of measurement. If we measure the sum of a sequence of single doses, then the error of measurement is negligible (relative to the amount of insulin delivered), which allows focusing exclusively on the error in insulin delivery.
As detailed in the Appendix, recovering single-dose characteristics from the combination of identically distributed doses is a commonly accepted technique using standard statistics based on assumption of independence of consecutive measurements-an assumption that is the basis for practically any statistical analysis. Most importantly, this is exactly the same assumption that would be used to estimate the SD of an individual dose if individual doses were measured. Thus there is no loss of generality in using a combination of doses compared with single doses.
In addition, as shown in the Appendix, the combined doses technique reduces the bias in estimation of the variance of delivered boluses in presence of measurement errors.
Results
At bolus dose of 0.05 U, mean delivered dose was 0.050 ± 0.003 U, 0.099 ± 0.005 U at 0.1 U, 0.2 ± <1e-5 U at 0.2 U, 1.001 ± 0.018 U at 1 U, and 6.03 ± 0.04 U at 6 U. The experiment environment was as follows: temperature 22.4-23.1 °C (72.4-73.6 °F) and barometric pressure 1015-1020 Pa (see Table 1 and Figures 6 and 7) .
Method 2

Spherical Bolus
We used a simple method of measurement using the microscope's field of view. If one knows the magnification power (150X in our case) along with a known measurement within the microscope's field of view [in this case, the outer diameter of the OmniPod's cannula (0.022 ± 0.0015 inches or 0.0558 ± 0.0038 cm)], then linear distances within the field can be measured (in this case, the diameter of the spherical bolus). Figure 4 shows the distal tip of the cannula and the spherical insulin bolus. From the diameter, one can derive the radius and thus the volume of the bolus using the following formula:
Two OmniPods were used in this experiment. The OmniPods were filled with Humalog insulin (Lilly) per the manufacturer's recommendations. Insulin was tinted with food coloring, just as in the previous method. Each Omni-Pod delivered 20 individual boluses of 0.05 U (0.5 µl). Using this method, we could actually measure the volume of each 0.05 U bolus as opposed to method 1, in which we needed to average the error after summing multiple boluses (see Figure 8) .
Results
The first OmniPod delivered an average bolus of 0.504 ± 0.013 µl (mean total diameter = 0.9879 mm). The second OmniPod delivered an average bolus of 0.506 ± 0.015 µl.
All results fall into the previously estimated 95% confidence interval. The experiment environment was as follows: temperature 22.2-22.7 °C (72-73 °F) and barometric pressure 1014-1016 Pa (see Table 2 ).
We have also compared the two methods by comparing the results for delivering 0.5 µl of insulin by the OmniPod (see Figure 9 ). Difference was found to be not statistically significant, p = .86.
Discussion
Insulin is often given in small doses (<1 U), especially to children and infants with type 1 diabetes. Dosing is weight adjusted, and precision is paramount. Overdosing insulin can cause life-threatening hypoglycemia, early symptoms of which small children or infants may not be able to identify or show. Underdelivering insulin is potentially dangerous due to development of acute DKA and long-term complications, such as cardiovascular disease, retinopathy, nephropathy, neuropathy. 7 Both extremes of hypoglycemia or hyperglycemia may lead to coma or death.
Insulin is currently administered via syringes, pens, or pumps. Several studies have assessed the accuracy of syringes and pens delivering low doses of insulin. [8] [9] [10] [11] A study by Keith and associates 8 compared accuracy of two syringes, three pens, and one pump. Syringes were found unacceptably inaccurate at doses lower than 5 U, overdosing by as much as 31% at a 1 U dose.
At the dose of 5 U, all devices were reasonably precise and accurate (<5% error for all devices), which was not true for smaller doses of 1 and 2 U. Pump (H-TRONplus V100, Disetronic Medical Systems Inc.) was the most precise device, with tendency to underdose. None of the devices were both precise and accurate at doses less than 5 U. In this review, we compared data from Keith and associates 8 to OmniPod data acquired by method 1, looking at the accuracy of different devices delivering 1 U of insulin. Other studies by Casella and coworkers, 9 Gnanalingham and colleagues, 10 and Lteif and Schwenk 11 produced similar results, concluding that syringes are very inaccurate and pens are more accurate than syringes at delivering small doses of insulin (<5 U). Another observation related to insulin pens noted during this project was that, if the plunger end of a pen was depressed after the dose had been administered, additional insulin was expressed from the needle tip. This amount was not quantified.
Continuous subcutaneous insulin infusion via pumps provides fewer fluctuations in insulin-glucose profile [12] [13] [14] [15] [16] [17] [18] There are limited data on insulin pump dosing precision, but several studies have shown that there are limitations in traditional pump design, which may adversely affect the treatment. The study by Zisser and associates 19 showed a siphon effect of conventional insulin pumps. In the benchtop study, changes in insulin delivery depend on the position of the cannula, ranging from 74.5% of expected dose when pumping upward to 123.3% when pumping downward at a rate of 1 U/h. Insulin delivery of the OmniPod system was not affected by pumping direction.
Two new approaches were applied to measure the volume delivery of the OmniPod insulin pump. Both methods require simple tools, are fast, and show good reproducibility. Method 1 showed OmniPod's high accuracy (>99%) and precision (93.3% to 99.4%), and method 2 confirmed these results at the lowest delivery volume, with all results falling into the 95% confidence interval estimated by method 1. In addition, there was no statistical difference between the results of method 1 and method 2 (t-test p = .86). Both methods can be applied for measuring volume delivery of other types of medical pumps as well.
In the future, visualization methods for quantifying amounts of insulin could be further optimized using image analysis software. For method 2, image analysis tools could be used to measure multiple diameters of the sphere and derive a measurement with a higher degree of accuracy.
Conclusion
Bench testing results obtained during two experiments showed that OmniPod is extremely accurate, with a relative error ranging from -0.9% to 0.96% for all doses (0.05, 0.1, 0.2, 1, and 6 U). This is much lower than any other insulin injection devices previously tested by Keith and associates 8 (see Figure 10 ), Gnanalingham and colleagues, 10 and Lteif and Schwenk. 
